US EditionScanCell’s Skin Cancer Vaccine Shows Phase 2 Promise, but Only One Candidate Moves Forward – Patient Worthy
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ScanCell’s Skin Cancer Vaccine Shows Phase 2 Promise, but Only One Candidate Moves Forward – Patient Worthy
ScanCell, a biotech firm focused on immunotherapies, announced promising results from Phase 2 clinical trials for its skin cancer vaccines, but only one of its two candidates will advance to the next stage of development. The announcement marks a significant step in the company’s efforts to harness the immune system to combat melanoma, a particularly […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium